SNGX (Soligenix) Growth Rank : 0 (As of Mar. 28, 2025)

View and export this data going back to 1994. Start your Free Trial

What is Soligenix Growth Rank?

Soligenix has the Growth Rank of 0.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability, rated on a scale from 1 to 10. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

A higher score reflects a greater ability to drive business growth, with companies considered to have strong and sustainable expansion potential. Conversely, a lower score indicates challenges in achieving consistent growth and scalability.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

Soligenix Growth Rank Related Terms

Thank you for viewing the detailed overview of Soligenix's Growth Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Soligenix Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Soligenix Inc (NAS:SNGX) » Definitions » Growth Rank

Comparable Companies

Traded in Other Exchanges

0A6I:UK

Address

29 Emmons Drive, Suite B-10, Princeton, NJ, USA, 08540

Website

https://www.soligenix.com

Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).

Executives

Timothy R. Cote	director	3529 TILDEN STREET, NW, WASHINGTON DC 20008
Richard Straube	officer: CMO	29 EMMONS DRIVE, SUITE C-10, PRINCETON NJ 08540
Christopher Schaber	director, officer: Chairman, CEO and President	29 EMMONS DRIVE, SUITE C-10, PRINCETON NJ 08540
Jonathan L. Guarino	officer: Chief Financial Officer	100 WELLESLEY WAY, FREEHOLD NJ 07728
Oreola Donini	officer: CSO	29 EMMONS DRIVE, SUITE C-10, PRINCETON NJ 08540
Robert J. Rubin	director	7901 SPRINGER ROAD, BETHESDA MD 20817
Anthony Gregg Lapointe	director	PO BOX 83216, GAITHERSBURG MD 20883-3216
Diane L. Parks	director	29 EMMONS DRIVE, SUITE B-10, PRINCETON NJ 08540
Jerome B Zeldis	director	8767 E. VIA DE VENTURA, SUITE 190, SCOTTSDALE AZ 85258
Mark E. Pearson	director, 10 percent owner	3031 TISCH WAY, SUITE 505, SAN JOSE CA 95128
Preta Martina Cavazza	other: Former 10% Owner	VIA SUDAFRICA 20, ROME L6 00144
Enrico Cavazza	other: Former 10% Owner	VIA PONTINA KM 30,400, POMEZIA (ROME) L6 00040
Silvia Cavazza	other: Former 10% Owner	VIA PONTINA KM 30,400, POMEZIA (ROME) L6 00040
Francesca Cavazza	other: Former 10% Owner	VIA PONTINA KM 30,400, POMEZIA (ROME) L6 00040
Spa Essetifin	10 percent owner	VIA SUDAFRICA 20, ROME L6 00144